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SUMMARY
Despite more cancers in young men over the past two decades, improvements in therapies give a greater chance to live full lives
following treatment. Sperm genomic quality is variable following cancer diagnosis, so its assessment is important if sperm cryop-
reservation is being considered. Here, we evaluated DNA damage using two DNA damage assays: an alkaline and for the first time, a
neutral Comet assays in men presenting with testicular cancer (n = 19 for alkaline and 13 for neutral group) and lymphoma (n = 13
for alkaline and 09 for neutral group) compared with fertile donors (n = 20 for alkaline and 14 for neutral group). No significant dif-
ferences were observed in any semen analysis parameters. In contrast, sperm DNA damage was higher in men with testicular cancer
than in donors as assessed by both the alkaline (12.4% vs. 37.4%, p < 0.001) and neutral (7.5% vs. 13.4%; p < 0.05) Comet assays. Sim-
ilar trends were observed in men with lymphoma. Here, sperm DNA damage was higher using both the alkaline (35.0% vs. 12.4%)
and neutral (10.7% against 7.5% (p < 0.05) Comet assays. Moreover, the DNA strand breaks (particularly double-strand breaks) were
significantly more prominent in men with cancer having abnormal seminal parameters than normozoospermic ones. This study
showed that sperm DNA testing using alkaline and neutral Comet assays is more sensitive than semen analysis in detecting impaired
sperm quality in men presenting with cancer. It may provide a useful adjunct when considering storage prior to cancer investigations
and assisted reproductive techniques (ART)-based treatment.
INTRODUCTION
The question about adverse effects of cancer on spermatoge-
nesis is still debated and has stimulated further research on
both quantitative and qualitative sperm parameters in oncolog-
ical patients (O’Flaherty et al., 2008; Smit et al., 2010; McDow-
ell et al., 2013; Paoli et al., 2015). Cryopreservation is the only
available preventive measure prior to cytotoxic therapies, and
it allows the use of frozen/thawed spermatozoa for assisted
reproductive techniques (ART). As the most important sperm
characteristic for fathering a healthy child is good sperm DNA
quality, it is important to determine the DNA quality of sper-
matozoa from men with cancer at the time of sperm cryop-
reservation. Damaged sperm DNA is negatively associated with
early fertility checkpoints such as fertilization rate, embryo
quality, implantation and positively with miscarriage [reviewed
by (Robinson et al., 2012)]. The majority of studies included in
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this meta-analysis of miscarriage data were by SCSA and
TUNEL were recruited. The quality of the paternal genome is
also associated with the later checkpoints in offspring health
(Lewis & Kumar, 2015). To date, however, there are conflicting
reports on the effect of cancer on sperm DNA (O’Donovan,
2005; O’Flaherty et al., 2008; Stahl et al., 2009; Smit et al., 2010;
McDowell et al., 2013; Paoli et al., 2015). Here, a novel sperm
DNA test specifically for double-stranded breaks (the neutral
single cell gel electrophoresis Comet) is compared with the
alkaline Comet detecting a combination of single- and double-
strand breaks. The study was designed to evaluate whether
both types of damage were induced by disease in men present-
ing with testicular cancer and lymphoma in comparison with
fertile donors.
Each test has its benefits and limitations and measures a
unique aspect of DNA damage. It is hypothesized that double-
stranded damage may have more adverse consequences than
single-strand breaks for later stages of fertility because the
oocyte has less capability to repair it following fertilization but
before the first cleavage (Alvarez, 2005). In most of the previous
studies, single assay was used to analyse the sperm DNA damage
level in men diagnosed with different types of cancer. In this
study, we evaluated the level of both double and double plus sin-
gle-stranded sperm DNA damage in men with reproductive and
non-reproductive cancers.
MATERIALS ANDMETHODS
Study samples
Men with testicular cancer or lymphoma attending the
Andrology Unit, Department of Clinical and Experimental Bio-
medical Sciences “Mario Serio”, University of Florence were
invited to participate in this study. The project was approved by
local research ethics and clinical governance committees and
written informed consent for participation was obtained from
each subject. Men presenting with testicular cancer (n = 19) or
lymphoma (n = 13) with normal or abnormal semen parameters
prior to cytotoxic therapy and 20 fertile donors (Cryos Interna-
tional, Denmark) were included in this study. Men with
azoospermia were excluded from the study. All fertile controls
had normal semen by WHO (2010) criteria, and none had any
history of infertility. All semen samples were obtained after 2–
7 days of sexual abstinence.
Semen and sperm DNA fragmentation (damage) analysis
All semen samples were examined for liquefaction time, pH,
semen volume, sperm concentration, sperm morphology, sperm
motility, according to World Health Organisation guidelines
(WHO, 2010). After collection of semen immediately, it was incu-
bated at 37 °C for 30–60 min for complete liquefaction. All the
seminal parameters were evaluated once the samples were com-
pletely liquefied. All semen samples were cryopreserved for the
later analysis of DNA damage. Rapid cryopreservation procedures
were used to freeze the spermatozoa from both fertile donors and
men presenting with cancer. Briefly, the sperm freezing media
were slowly mixed (dropwise) with the semen and left for incuba-
tion for 10 min at room temperature. Then the mixture was trans-
ferred to straws or cryovials and equilibrated horizontally above
liquid nitrogen vapour for 30 min. Finally, the cryovials/straws
were plunged into liquid nitrogen and transferred to storage tank
until further use. Unless otherwise stated, all the reagents were
purchased from Sigma-Aldrich, England, UK.
Alkaline Comet assay
Sperm DNA fragmentation was assessed using an alkaline sin-
gle cell gel electrophoresis assay as reported previously (Hughes
et al., 1997; Donnelly et al., 1999). Briefly, the semen sample
concentration was adjusted to 2 9 106/mL in PBS. Fully frosted
slides (Surgipath Europe, UK) were layered with 150 lL of 1%
normal melting agarose (NMA) and immediately covered with a
coverslip. Once the NMA had solidified, the coverslip was
removed and immediately layered with a mixture of 10 lL of
diluted sample (2 9 106/mL in PBS) and 75 lL of 0.5% low melt-
ing agarose (LMA). The slides were quickly covered with a cover-
slip and allowed to solidify at room temperature. Once LMA
solidified, the coverslip was removed and slides were immersed
in a coplin jar containing lysis solution (2.5M NaCl, 100 mM
Na2EDTA and 10 mM Tris-HCl, pH 10) with 1% Triton X-100, for
1 h at 4 °C. Slides were further incubated for 30 min at 4 °C with
dithiothreitol (10 mM) followed by 90 min incubation at room
temperature with lithium diiodosalicyclate (4 mM) to decon-
dense the DNA. Slides were then incubated with cold alkaline
electrophoresis buffer (300 mM NaOH, 1 mM EDTA) for 20 min
to unwind the DNA. The slides were further subjected to elec-
trophoresis using cold alkaline electrophoresis buffer for 10 min
at 25 V, with the current adjusted to 300 mA. Then slides were
removed from electrophoresis tank and were neutralized in neu-
tralization solution (0.4 M Tris-HCl, pH 7.5). Finally, slides were
stained with 30 lL of 20 mg/mL ethidium bromide and analysed
immediately. At least 50 Comet images were analysed using
image analysis software (Komet 6, Andor Technology, Belfast,
UK), and the results were expressed in percentage tail DNA.
Neutral Comet assay
Double-stranded sperm DNA fragmentation was assessed using
single cell gel electrophoresis (Neutral Comet) assay. To establish
the efficient neutral Comet assays experimental conditions, the
procedures described by Ribas-Maynou et al. (2014) were applied
with modifications in the initial lysis steps and electrophoresis
optimized in the first author’s laboratory. The initial preparation
of slides with agarose and sample was similar to the alkaline assay
as stated above. Once the slide completely solidified with agarose,
slides were then treated with 1% Triton X-100 solution for 30 min
at room temperature (RT). Next, slides were washed in 0.9% NaCl
solution three times for 5 min and then washed two times for
5 min in PBS. Control slides were treated with 15UI Alu I restric-
tion enzyme for 30 min at 37 °C. All slides were then incubated for
30 min at RT in lysis buffer I (TRIS-HCl 0.4 M, DTT 0.8 M, SDS 1%,
pH 7.5), followed by 30 min at RT in lysis buffer II (TRIS-HCl
0.4 M, NaCl 2 M, DTT 0.4 M, Na2EDTA 50 mM, pH 7.5), followed by
30 min at RT in lysis buffer III (TRIS-HCl 0.4 M, SDS 1%, DTT
0.8 mM, pH 7.5) in the fume hood. Following this, slides were
rinsed in cold TBE electrophoresis buffer (TRIS-HCl 0.445 M, Boric
acid 0.445 M, 10 mM EDTA, pH 7.5) for 10 min. Electrophoresis
was carried out in a cold room with cold TBE electrophoresis buf-
fer. Slides were submerged, and electrophoresis was run at 20 V
(1 V/cm) for 8 min. Following electrophoresis, slides were rinsed
in 0.9% NaCl and stained with 30 lL of 20 lL/mL of ethidium bro-
mide. Fifty Comets per slide were scored with KOMET 6 software
(Komet 6, Andor Technology).
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Statistical analysis was performed using the Statistics Package
for the Social Sciences software, version 21 (SPSS Inc., Chicago,
IL, USA). Comparisons of seminal parameters between (testicu-
lar cancer and lymphoma) men with cancer were assessed using
the non-parametric Mann–Whitney U-test as the data were not
normally distributed. Similarly, Mann–Whitney U-test was also
used for the comparisons of DNA damage between men with
testicular cancer and lymphoma and healthy donors. Data pre-
sented correspond to the median (minimum–maximum) and
interquartile range. For all statistical analysis, p < 0.05 was con-
sidered significant.
RESULTS
Semen parameters in men with testicular cancer and
lymphoma
All median semen parameters of both groups were above the
WHO (2010) cut-off values with no significant differences were
found in any conventional semen parameters between the two
cancer groups (Table 1). However, abnormal semen parameters
were present in 63% and 46% of men with testicular cancer and
lymphoma respectively. All fertile donors had high semen qual-
ity with all sperm parameters above WHO (2010) lower reference
limits.
Comparison of sperm DNA fragmentation between men
presenting with testicular cancer, lymphoma and fertile donors
In contrast to seminal parameters, sperm DNA fragmentation
was significantly higher in men with testicular cancer than in the
control group as assessed by both the neutral (n = 13) (7.5% vs.
13.4%; p < 0.05) and alkaline (n = 13) (12.4% vs. 37.4%,
p < 0.001, Table 2) Comet assays. Similar results were obtained
for men presenting with lymphoma. Sperm DNA fragmentation
(a combination of both double and single strands) of 35.0%
against 12.4% in donor group (p < 0.001 using the alkaline
Comet), whereas DNA fragmentation of 10.7% against 7.5
(p < 0.05; using the neutral Comet) (Table 2). Marked increases
of 78% and 42% in double-strand breaks were observed in sper-
matozoa from men with testicular cancer and lymphoma,
respectively.
Moreover, a comparison of double plus single- and double-
stranded DNA damage only from men with each type of can-
cer subdivided into those with normal and abnormal semen
parameters was also performed. DNA fragmentation level
detected by Comet assays tended to be higher in those with
abnormal semen parameters group compared to cancer men
with normal semen.
In men presenting with testicular cancer, both those with
normal and abnormal semen had high levels of single- and dou-
ble-stranded DNA damage. In contrast, only those men with
abnormal semen had high levels of double-stranded damage, in
fact, it was 1.5 times higher than in those with normal semen
and double than donor group (14.12% vs. 9.61&7.5%). Those
with normal semen had levels of double-stranded breaks similar
to the fertile donors (Table 3).
Also, in men presenting with lymphoma, the trends were simi-
lar. There was little difference with sperm DNA fragmentation
levels of 34.81% and 36.05% being observed in normal and
abnormal semen parameters groups, respectively, as measured
by alkaline Comet assay. In contrast, the double-stranded dam-
age was double in the men with abnormal semen compared to
those with normal semen and also to donors (19.11% vs. 9.83
and 7.5%) (Table 3).
DISCUSSION
Data in the literature are conflicting as to the quality of semen,
as assessed by a conventional semen analysis, in men presenting
with cancer (Rives et al., 2012; McDowell et al., 2013; Caponec-
chia et al., 2016). In this study, we found no significant reduc-
tions in sperm concentrations, motility or morphology in men
Table 1 Semen parameters in men at the time of cancer diagnosis compared to WHO reference limits for fertile men
Semen parameters aWHO 2010 lower
reference limits
Men with
lymphoma (n = 13)
Men with testicular
cancer (n = 19)
Mann–Whitney
U-test
Sperm concentration (106/mL) 15 (12–16) 44.7 (9.0–80.0, 51.0) 24.0 (3.20–82.0, 25.0) p = 0.099
Total sperm number 39 (33–46) 119.7 (20.37–336.0, 158.3) 38.0 (5.76–246.0, 100.2) p = 0.120
Motility (PR, %) 32 (31–34) 63.0 (6.0–73.0, 22.5) 59.0 (3.0–83.0, 48.0) p = 0.631
Morphology (%) 4 (3.0–4.0) 4.0 (0–8.0, 3.5) 4.0 (1.0–10.0, 3.0) p = 0.684
aLower reference limits (5th centiles and their 95% confidence intervals) for WHO semen parameters values; All values in patient groups are median (minimum–maxi-
mum, interquartile range.)
Table 2 Comparison of sperm DNA damage using alkaline and neutral Comet assays in men with testicular cancer and lymphoma
DNA
damage
assays
Men with lymphoma vs. donors sperm DNA damage (%) Men with testicular cancer vs. donors sperm DNA damage (%)
Donors DNA damage (%) Percentage
difference
(%)
Mann–
Whitney
U-test
Donors DNA damage (%) Percentage
difference
(%)
Mann–
Whitney
U-test
Alkaline
Comet
assay
12.4 (5.3–18.8, 7.2)
(n = 20)
35.0 (17.93–53.34,8.65)
(n = 13)
+182 p < 0.001 12.4 (5.3–18.8, 7.2)
(n = 20)
37.4 (17.42–49.42, 12.8)
(n = 19)
+201 p < 0.001
Neutral
Comet
assay
7.5 (5.9–15.1, 3.7)
(n = 14)
10.7 (7.9–37.1,9.3)
(n = 09)
+42 p = 0.012 7.5 (5.9–15.1, 3.7)
(n = 14)
13.4 (4.3–19.6, 5.7)
(n = 13)
+78 p = 0.010
All values are median = /-minimum–maximum and interquartile range. Mann–Whitney U (M–W test)-test was used to test significance at p < 0.05.
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with either form of cancer compared to WHO lower reference
limit for fertile men (WHO, 2010). However, in agreement with
other larger studies, we observed a trend towards poorer seminal
values in men with testicular cancer compared to men present-
ing with lymphoma (Williams et al., 2009; Caponecchia et al.,
2016). Furthermore, men with abnormal seminal parameters in
testicular cancer and lymphoma were oligozoospermic (OZ),
oligoasthenozoospermic (OAZ), oligoteratozoospermic (OTZ),
oligoasthenoteratozoospermic (OATZ), asthenoteratozoosper-
mic (ATZ) and teratozoospermic (TZ) wherein OZ, OAZ, OTZ,
OATZ and ATZ were common in both types of cancer as
observed by previous studies (Chung et al., 2004; Djaladat et al.,
2014). In this study, semen parameters fell within the normo-
zoospermic category in 37% and 54% men with testicular cancer
and lymphoma, respectively.
The literature is also contradictory concerning sperm DNA
fragmentation, reporting both significantly higher (Gandini
et al., 2000; O’Flaherty et al., 2008, 2012; Stahl et al., 2009) and
similar (Ribeiro et al., 2008; Smit et al., 2010; McDowell et al.,
2013) DNA quality in men presenting with cancer to healthy
men. In our study, by performing alkaline and neutral Comet
assays, we observed high levels of both single and double DNA
strand breaks in men presenting with cancer indicating a poten-
tial adverse genomic effects of this disease. The Comet assay has
a higher sensitivity than other assays, and it can provide more
information about the extent and heterogeneity of DNA (Godard
et al., 1999; Kindzelskii & Petty, 2002; Simon et al., 2014). The
ability of the Comet to detect degrees of DNA damage in individ-
ual spermatozoa rather than an overall percentage of damaged
spermatozoa in a semen sample makes it more suitable than
other assay as a diagnostic test in this context. The Comet assay
under alkaline conditions (pH ≥13) detects both single- and dou-
ble-strand breaks while under neutral conditions it detects only
double-strand breaks (DSBs) (Olive et al., 1991; Collins, 2002). A
further advantage is that unlike some other tests that detect pri-
marily breaks in histone-associated chromatin, the Comet assay
has a greater capacity to detect DNA damage because the Comet
procedure removes all nucleoproteins revealing breaks in DNA
associated with both protamine- and histone-bound chromatin.
In addition, Comet assay detects real than potential damage and
our research group and others have reported that sperm DNA
damage in native and density centrifuged spermatozoa mea-
sured by the alkaline Comet assay has been significantly associ-
ated with ART outcomes (Morris et al., 2002; Simon et al., 2013).
In men with testicular cancer, O’Donovan (2005)reported a sig-
nificant difference of Comet head DNA integrity between cancer
patients and controls (49.87 vs. 86.91%). Similarly, O’Flaherty
et al. (2008) reported higher levels of sperm DNA damage (comet
tail extent moment) in men presenting with testicular cancer
(12.0 vs. 30.0) and Hodgkin’s lymphoma (12.0 vs. 25). Like-
wise, using the alkaline Comet assay in this study, we report
three times more DNA damage in men with testicular cancer
and lymphoma compared to donor groups.
Also, an increased sensitivity of the neutral Comet assay with
respect to other assays have been demonstrated in somatic
cells (Yasuhara et al., 2003). The neutral version of the Comet
is the latest DNA test to be added to the range of DNA tests
currently being used in ART. Its major advantage is that, unlike
any of the other tests, it detects double-stranded breaks exclu-
sively. Although the number of studies on neutral Comet
assays is limited, few studies showed that DNA damage
detected by neutral Comet assay could prove to be good prog-
nosis in cases of male infertility and male partners of unex-
plained recurrent abortion couples with no detectable female
factors (Ribas-Maynou et al., 2012a,b; Zhong et al., 2015).
Indeed, sperm double-strand DNA breaks fragmentation exam-
ined by the neutral Comet assay significantly correlated with
sperm nuclear vacuoles, an important parameter for sperm
selection for ART treatment (Pastuszek et al., 2017). Moreover,
sperm DNA fragmentation assessed by this assay associated
with chromosome rearrangements causing aneuploidy in the
fertilized embryos (Ramos et al., 2015). Under neutral
Table 3 Comparison of sperm DNA fragmentation in cancer men with normal and abnormal semen parameters
Assays Fertile donors Men with lymphoma M–W test
(Control vs. NS)
M–W test
(Control vs. AS)
Donors Normal semen (NS) Abnormal semen (AS)
Alkaline Comet 12.4 (5.3–18.8, 7.2)a (n = 20) 34.81 (17.93–45.86, 9.70)b (n = 07) 36.05 (33.91–53.34, 10.98)c (n = 06) avsbp < 0.001 avscp < 0.001
Neutral Comet 7.5 (5.9–15.1, 3.7)d (n = 14) 9.83 (8.14–16.14, 6.43)e (n = 04) 19.11 (10.61–37.12, 14.47)f (n = 05) dvsep = 0.137 dvsfp = 0.003
Assays Fertile donors Men with testicular cancer M–W Test
(Control vs. NS)
M–W Test
(Control vs. AS)
Donors Normal semen(NS) Abnormal semen (AS)
Alkaline Comet 12.4 (5.3–18.8, 7.2)g (n = 20) 39.06 (19.45–49.42, 17.46)h (n = 07) 37.28 (17.42–49.31, 12.50)i (n = 12) gvshp < 0.001 gvsjp < 0.001
Neutral Comet 7.5 (5.9–15.1, 3.7)j (n = 14) 9.61 (4.30–16.20, 6.73)k (n = 05) 14.16 (9.97–19.6, 3.50)l (n = 08) kvsmp = 0.405 kvsnp = 0.003
All values are median = /-minimum–maximum and interquartile range. M–W Test (Mann–Whitney U-test) was used to test significance at p < 0.05.
aMedian alkaline assay sperm DNA fragmentation level in Fertile donors.
bMedian alkaline sperm DNA fragmentation level in men with lympohoma having normal semen parameters.
cMedian alkaline sperm DNA fragmentation level in men with lympohoma having abnormal semen parameters.
dMedian neutral assay sperm DNA fragmentation level in Fertile donors.
eMedian neutral sperm DNA fragmentation level in men with lympohoma having normal semen parameters.
fMedian neutral sperm DNA fragmentation level in men with lympohoma having abnormal semen parameters.
gMedian alkaline assay sperm DNA fragmentation level in Fertile donors.
hMedian alkaline sperm DNA fragmentation level in men with testicular cancer having normal semen parameters.
iMedian alkaline sperm DNA fragmentation level in men with testicular cancer having abnormal semen parameters.
jMedian neutral assay sperm DNA fragmentation level in Fertile donors.
kMedian neutral sperm DNA fragmentation level in men with testicular cancer having normal semen parameters.
lMedian neutral sperm DNA fragmentation level in men with testicular cancer having abnormal semen parameters.
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conditions, here we report a significant difference in DNA dou-
ble-strand breaks compared to fertile donors in men present-
ing with testicular cancer and lymphoma. Although some of
the differences observed between donors and disease samples
from men presenting with cancer may be due to inherent vari-
ability, of human of sperm quality, the marked differences sug-
gest a specific contribution from the disease per se. Here,
significantly higher double-strand breaks were observed in
both groups of men with cancer compared with healthy
donors, but double-strand breaks were more prominent in
men with testicular cancer than in those affected by lym-
phoma suggesting a potentially stronger association of the
reproductive testicular cancer with sperm chromatin quality
than non-reproductive cancer. Interestingly, in the current
study, as double-strand breaks were more prominent in men
with abnormal semen in both types of cancer, a potential asso-
ciation that needs further investigation.
Moreover, fatherhood in cancer survivals is conflicting in the
literature reporting both high (Brydoy et al., 2005) and low
paternity rate (Saxman, 2005). Knowing the detrimental effect of
the cancer itself (especially in the case of testicular cancer) and
the effect of cytotoxic treatments, men with cancer should be
guided to preserve their reproductive potential through sperm
cryopreservation. To date, this often results in men with onco-
logical disease becoming fathers through ART. Double-strand
DNA damage could be a predictor for successful ART outcomes
in cancer survivors as proposed recently for infertility treatment
(Garolla et al., 2015). It is important clinically as the oocyte may
have more difficulty locating and repairing double-strand breaks
post-fertilization possibly leading to genomic instability in the
developing embryo. Hence, clinicians undergoing subspeciality
training in andrology should be taught about preventive proce-
dures and monitoring of sperm DNA integrity in men presenting
with cancer before and after cytotoxic treatments (Krausz et al.,
2015).
In summary, the characterization of single- and double-strand
DNA breaks in spermatozoa has provided additional important
data to indicate that sperm DNA is already damaged at diagno-
sis, irrespective of cancer treatment. Double- and single-strand
breaks are common in both types of cancer and detected at
higher levels in men who also have abnormal semen. Thus, the
Comet assays provide the basis of potential tests for screening
out samples that may be unsuitable for future clinical use.
Sperm DNA damage is a useful bio-marker when considering
storage prior to treatment and thus its future use for ART.
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